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A number of previous reports (1-4) have indicated that recombinant and
hybrid IFN, as well as natural IFN vary considerably in their ability to mediate
biological activities. Recent studies (4, 5) have also shown that NK activity can
be significantly augmented by natural and recombinant species of IFN-a. In
addition to IFN, IL-2 has been reported (6-10) to play a major role in many
types ofimmune responses. This lymphokine induces proliferation ofT lympho-
cytes and NK cells and the production of IFN-y; it also results in the induction
of lymphokine-activated killer (LAK)' cells against previously NK-resistant cell
preparations andcell lines (7-11). LAK cells induced by IL-2 arepotent cytotoxic
cells that may have an important role in immunotherapy ofsolid tumors.
In the studies reported here, we separated normal lymphocytes into large
granular lymphocytes (LGL) and T lymphocyte subsets by fractionation on
Percoll density gradients. Selected leukocyte subpopulations were subsequently
depleted with antibody and immunoadsorbent techniques. After purifying leu-
kocyte subsets, we determined which of them generated LAK activity in the
presence of IL-2. Similarly, we were able to determine the phenotype of LAK
effector cells by generating LAK activity from unseparated peripheral blood
mononuclear cells and then selectively depleting various lymphocyte subsets. In
addition, we used a sensitive limiting-dilution frequency assay to examine unsep-
arated leukocytes and subpopulations of lymphoid cells for their ability to act as
progenitors and effectors of LAK activity.
Finally, because ofrecent reports (11) regarding the role ofthe Tcell receptor
in mediating cytolytic activity against target cells, we examined the effect of
antibodies against a CD3 molecule as well as other molecules to study their
possible relationship to the generation ofcytotoxic activity.
Materials and Methods
Preparation of Target Cells.
￿
The following tumor cell lines were used as targets in the
cytotoxicity assay: K562, derived from a patient with chronic myelogenous leukemia in
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blast crisis (12); MBL2, a Moloney leukemia virus-transformed cell line (13); FEMX, a
human melanoma cell line (14) ; and fresh, noncultured, human tumor cells obtained from
frozen aliquots isolated from ascites fluid of a patient with ovarian adenocarcinoma.
Aliquots of fresh tumor cells were frozen and used for individual assays (6). Target cells
were cultured at 37°C in a humidified atmosphere of air with 5% C02 in RPMI 1640
medium (Biofluids, Inc., Rockville, MD) supplemented with 10% human AB serum (Gibco,
Grand Island, NY), 0 .3 mg/ml glutamine, 100 IU/ml penicillin, and 10 Ag/ml strepto-
mycin. The culture lines were initiated at 0 .3 X 106 cells/ml. When cell density reached
or approached 2 X 106 cells/ml, we centrifuged the cells at 120 g for 10 min, discarded
the supernatant, and collected the cell pellet.
IsolationofLGL and TLymphocytes.
￿
LGL and T lymphocytes were obtained from buffy
coats of peripheral blood from normal healthy volunteers, as previously described (15,
16). Briefly, mononuclear cells were separated by centrifugation on a Ficoll-Hypaque
gradient and depleted of monocytes by adherence on a plastic surface. Nonadherent cells
were applied to a nylon wool column, and the eluted cells were then fractionated on a
seven-step discontinuous gradient of Percoll (Pharmacia Fine Chemicals, Uppsala, Sweden)
at concentrations of 40-60% (15). LGL were collected from the low-density fractions
(fractions 2 and 3, counting from the top), whereas T cells were found in the higher-
density bottom fraction. Contaminating T lymphocytes were further removed from the
LGL fraction by rosetting with SRBC at 29 °C for 1 h (16). The LGL, which do not form
rosettes at this temperature, were recovered from the interface of a Ficoll-Hypaque
gradient. LGL-enriched preparations contained an average of 80-90% LGL, as deter-
mined by morphological analysis of Giemsa-stained cytocentrifuge preparations, and were
70-75% OKM1+, 75-80% CDw16+ (Leu-11), and <5% CD3+ cells, as determined by
flow cytometry (16). Hereafter, this cell preparation will be referred to as the unfraction-
ated or whole LGL population. Purified T lymphocyte preparations contained <I% LGL
and were >95% CD3+ (16).
Cytotoxicity Assay.
￿
Target cells were labeled with 100 ACi 5' Cr (New England Nuclear,
Boston, MA) for 1 h at 37 °C, and extensively washed before use. Target (5 X 10') and
effector cells in 0.1 ml of medium were plated in microtiter plates at several E/T ratios
(25 :1, 12:1, 6:1, 3 :1) . After a 4-h incubation at 37'C, the supernatants were harvested
and counted in a gamma counter. Cytotoxicity was determined by the amount of "Cr
released from dead target cells. Three replicates were used for each experimental group,
and the percent specific lysis was calculated as 100 X [(cpm in experimental wells) - (cpm
in wells with target cells alone)]/(cpm incorporated into target cells). A lytic unit (LU) is
defined as the number of cells mediating 30% lysis (6). An increase in isotope-release
levels of 6% above baseline was consistently statistically significant (p < 0.05 Student's t
test).
Culture Medium.
￿
Culture medium was RPMI 1640 supplemented with 10% human
AB serum (M. A. Bioproducts, Walkersville, MD), 0 .1 mM nonessential amino acids
(Gibco), 2 mM sodium pyruvate (Gibco), 4 mM glutamine (National Institutes of Health
Media Unit, Bethesda, MD), 50 ,ug/ml gentamicin (Sigma Chemical Co., St. Louis, MO),
and 2.5 X 10-5 M 2ME (Sigma Chemical Co.). This medium will be referred to hereafter
as complete medium.
Treatment and Separation of Cells with mAbs.
￿
The following mAbs were used in this
study: CD3 (OKT3, Leu-4) (pan-T antigen), CD8 (OKT8; suppressor/cytotoxic T cell),
CD4 (OKT4; helper/inducer T cells), CDw16 (3G8 ; Fcy receptor on LGL and neutro-
phils), and NKH1 (reactive on most LGL ; a gift from Coulter Immunology, Hialeah, FL)
and Leu-M3 (monocytes) was used as a control Ig reagent .
Cells were treated with mAbs according to the following procedures: 5 X 106 LGL
were labeled with 20 jI mAb at the concentration of 1 t+g/ml in 0.1 ml of PBS with 1
FCS (Gibco) for 45 min at 4°C. At the end of the incubation, the cells were washed twice
with PBS.
Separation ofLymphocyte Subsets with Immunoadsorbent Plates (IAP).
￿
Lymphocyte subsets
were separated on an anti-F(ab')2 IAP by modification ofthe methods previously described
(18, 19). Affinity-purified F(ab')2 goat anti-mouse IgG (Cappel Laboratories, West Ches-ORTALDO ET AL.
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ter, PA or Boehringer Mannheim, Indianapolis, IN), at 10 mg/ml, was immobilized on 7-
cm plastic dishes for 2-18 h at VC. C. Binding efficiency of the protein ranged from 40 to
70%, as determined by measuring the reduction in the optical density of the protein
solution with a spectrophotometer (Gilford Instrument Laboratories, Inc ., Oberlin, OH)
at 280 nm (after the coupling). Before use, plates were washed with RPMI 1640 containing
10% FCS and incubated at 37° C for 30 min. mAb-treated cells, at 107 cells/ml (total of
5 ml/dish) were put onto the IAP. Plates were incubated for 60 min at 4°C . Medium plus
EDTA (1 mM) was gently poured on top of the plate, and negative (nonadherent) cells
were collected in 10-15 ml. Positive (adherent) cells were detached using a cell scraper,
and collected by washing. Reanalysis of the isolated population revealed that positive
fractions contained <2% inappropriate cells, whereas negative fractions contained up to
10%.
Limiting-dilution Analysis (LDA).
￿
In the LDA, culture medium was supplemented with
500 U/ml rIL-2 obtained from Biogen, Inc. (Cambridge, MA). LDA were performed as
previously described (20). Briefly, responder cells (ranging from 10,000 to 10 cells/well,
12 replicates per concentration) were dispensed in 0.1 ml of complete medium containing
IL-2 into round-bottom, 96-well plates (Linbro Chemical Co., Hamden, CT). Autologous
irradiated (3,000 rad) mononuclear cells (2 X 105 cells/well) were added in 0.1 ml. Each
well received a total volume of 0 .2 ml. Plates were cultured for 7 d to determine the
frequency of proliferating cells, and for 8 d in studies of cytotoxic precursor frequency.
These incubation times have been found to be optimal for such studies (17). To determine
frequency of cytotoxic progenitor cells, plates were washed in medium without IL-2 6-8
h before the cytotoxicity assay to reduce possible nonspecific lysis (9, 10). Medium (0.1
ml) was replaced with 5'Cr-labeled target cells (5 X 10' cells/well).
Proliferation was assessed by measuring the cells' uptake of [sH]thymidine (sp act, 6.7
mCi/mmol; New England Nuclear) during the last 18 h of incubation. Each well received
1 jCi of [sH]thymidine. The cells were then harvested onto glass fiber discs with an
automatic harvester, and radioactivity was measured in a liquid scintillation counter.
Assessment of LDA Results.
￿
Background control values were determined by measuring
the uptake of [5H]thymidine and release of "Cr in wells (24 replicates) containing
autologous feeder cells with medium plus IL-2 . Test wells were considered positive when
values exceeded the mean control value by three standard deviations. Using linear
regression analysis, the minimum estimate of frequencies was calculated as the number of
responder cells plated relative to the log of the percentage of negative wells (37%). The
significance of differences between different lines of responder cells within the same
experiment was calculated as described by Taswell (20).
Results
Characterization of LAK Precursors.
￿
Leukocyte subpopulations were fraction-
ated and tested for theirability to generate LAK activity after 3-5 d of incubation
in rIL-2. Initially, enriched populations of LGL and T cells were prepared from
mononuclear PBL (Table 1). In more than 10 experiments, the LGL-rich
fractions consistently demonstrated higher levels ofrIL-2-generated LAK activity
against fresh ovarian carcinoma (OVCA) cells and FENIX (human melanoma
cells), than did the T cell-enriched fractions. We also saw high levels of activity
against NK-sensitive K562 cells. To further characterize the precursor cells
capable of generating LAK cells, subsets of PBL enriched to express CDw16 or
CD3 were cultured in rIL-2 for 3-4 d (Table 11). LAK activity was generated
from several of these subsets . As with the Percoll-isolated cells, the LGL-rich
populations (CDw16+, NKH1 +) were the most active. However, the T cell-rich
population, CD3+, also had considerable cytotoxic activity. Cytotoxic activity
against NK-sensitive and -resistant targets could be efficiently generated in Fc'yR-
LGL after 3-5 d in culture with rIL-2 . LAK cells generated from unseparated1196
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TABLE I
LAK Activity in Subpopulations ofLeukocytes Isolated on
Percoll Gradients
Cells staining positively on
Cell type
￿
day 4 for:*
* Surface markers were anal zed by flow cytometry.
Cytotoxic activity in a 4-h 11 Cr-release assay.
LAK Activity in Subpopulations of Leukocytes Isolated with mAbs
Cells staining positively for markers on:*
￿
Cytolytic activityagainst target cells.~
TABLE II
Cytolytic activity*
* Leukocyte subpopulation isolated by IAP.
# Percent positive cells determined by flow cytometry.
4 LU/10' effector cells, ofphenotype indicated, measured in a 4-h "Cr-release assay. Total lytic units was calculated from cell recovery.
peripheral blood mononuclear cells or purified T cells also mediated significant
cytotoxicactivity, but required substantially more effector cellsto mediatesimilar
levels oflysis. When the ability of thevarious phenotypically characterizedsubsets
to mediate cytotoxicity is analyzed on the basis of the total amount of cytotoxic
activity, it is clear that the contribution of T cells to the total number of lytic
units in the population is variable (depending on target cell), but is generally in
the range of 15-50% of the total cytotoxic activity, and therefore the LGL
fraction routinely contributes >50% of the total cytotoxic activity. Based on
these results, physical separation of cells could result in isolation of the majority
of LAK activity within a minor lymphocyte subset. Fig. 1 graphically demon-
strates the relative contributions of LGL and T cells to the generation of LAK
activity. If one examines cell recovery and lytic activity against FEMX cells, one
can see that a 45 .8% Percoll cut-off results in a restriction of 69% of the total
lytic activity within 13 .7% ofthe total number ofcells. This findingwas consistent
in several experiments, where the majority (>60%) of the lytic activity was
restricted to 15-20% of the total number of cells (generally, those cells that are
isolated from 46% Percoll fractions).
Further studies were performed to exclude the possibility that activity gener-
ated from T cells was due to contamination by NK cells. CDw16' and OKMI'
cells were depleted from the Percoll-isolated T cell population. Treating the T
Leukocyte sub- Day 0 Day 4 K562 FEMX OVCA
population*
CD3 CDwl6 NKH1 CD3 CDwl6 NKH1
LU/10'
cells
Total LU
LU/10'
cells
Total
LU
LU/10'
cells
Total
LU
PBL 95 8 10 96 12 14 207 175 59 28 16 14
CD3* a98 52 52 a98 52 3 15 32 17 43 12 35
CD3- 11 94 >97 8 59 95 307 209 108 76 60 43
CDw16* 52 a97 a97 7 59 84 285 192 125 88 81 50
CDwl6- 2:97 52 52 92 52 4 22 40 10 31 8 21
CD3 Leu-11 NKH1 K562 OVCA FEMX
LU/10' cells
PBL 90 6 8 401 9.0 38
LGL 4 63 83 725 35 109
T >>-97 <<-1 3 301 12 9ORTALDO ET AL.
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FIGURE 1.
￿
Relative activity level of Percoll-isolated lymphocytes. Figure shows LU/107 cells
(bars) as well as the total cell recovery (O). The total LU and the total cell recovery are
summarized. Theresultsshow cytotoxic activity against FENIX target cells after4d incubation
with 500 U/ml human rIL-2.
cell fraction with antibodies routinely used to deplete NK cells did not alter the
ability ofCD3+ T cells to generate LAK activity (data not shown).
Kinetics of LAK Generation by LGL and T Cell Subpopulations.
￿
The data
presented above demonstrate that both T cells and LGL contributed to rIL-2-
generated LAK activity. Therefore, we investigated whether the kinetics ofLAK
cell generation with rIL-2 differed between these subpopulations. LGL and T
cells were culturedfor 1-5 d in 500 U/ml IL-2-containing medium. Interestingly,
the PBL and T cellpopulations wereconsistently slower togenerate LAKactivity,
with the maximal level ofactivity appearing on day 2 or later (Fig. 2). However,
when LGL-enriched populations were used, high levels ofcytolytic activity were
seen against tumor cells by day 1. These results indicate either that LGL can be
activated more rapidly than Tcells or that cell-cell interactions occur in the LGL
population such that the development of LAK activity is optimized. Therefore,
it appears that activated NK and Tcells kill fresh tumor cells, but that these two
cell types generate those activities at different rates.
Frequency of LAK Progenitors.
￿
To directly examine the actual progenitor
frequencies ofthese various populations, limiting-dilution frequency analysis was
performed. Fig. 3 illustrates a typical result, where unseparated lymphocyte
populationsand various subsets ofcellsisolated on Percoll density gradients were
examined for their ability to generate LAK cells. These cells were plated in a
limiting-dilution analysis on day 0, and their cytotoxic activity was analyzed on
day 4. As in other experiments, the activity level was highest in the first three
Percoll fractions. The results of these assays also directly demonstrate that the
frequency ofprogenitors is highest in the first two fractions from Percoll density
gradients. In comparison to the unseparated lymphocyte populations, there is a
^-10-50-fold increase in the number ofprogenitors present in fractions 1 and 2.
Fractions 4, 5, and 6, which are primarily T cell-enriched populations, generate1198
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FIGURE 2.
￿
Kinetics of LAK generation by LGL and T cell subsets. The kinetics o£ lysis of
OVCA, MBL2, and FEMX cells by unseparated lymphocyte (/) and Percoll-isolated LGL (O)
or T cell (0) fractions are shown.
precursor frequencies (^1/105) similar to those observed in the unseparated
populations. Therefore, the low-density (LGL-enriched) fractions are capable of
generating more cytotoxic activity (as measured in LU) and the frequencies of
progenitor cells are considerably higher in this population than in the unsepa-
rated populations or in other subsets of cells prepared from Percoll gradients.
Characterization of Effector Cells Mediating LAK Activity.
￿
Experiments were
performed to analyze the phenotype(s) of cells capable of mediating the broad-
spectrum cytotoxic activity generated when unseparated lymphoid cells were
cultured in rIL-2. The data presented in Table III wereobtained after peripheralM O
to
FIGURE 3.
￿
Frequency analysis of LAK progenitor. Limiting-dilution frequency analysis of
LAK progenitor cells was performed on day 0. The effector function of the various dilutions
wasmeasured forcytotoxicity against FEMX target cells on day 4. Results show thefrequency
(±95% confidence interval) based on limiting-dilution X' analysis.
Characterization ofEffector Cells MediatingLAKActivity
ORTALDO ET AL.
PBL
￿
F1'1
￿
R' 2
￿
Fr 3
￿
R'4
￿
R'5
￿
R'6
Pop"on
TABLE III
1199
Characterizations performed 4 d after IL-2 activation ofeffector cells separatedby IAP on day 0.
blood mononuclear cells had been cultured for 4 d in the presence of 500 U/ml
HL-2. The cultured effector cells were divided into CD3+ and CD3- or CD8
and CD8- sets. Analysis of the cytotoxic activity ofthese various subsets against
NK-susceptible K562 cells and NK-resistant MBL2 and fresh human OVCAcells
showed that CD3- lymphocytes mediated the highestlevels ofcytotoxicity against
all three targets (data not shown). Interestingly, a high percentage (97%) ofthese
CD3- cells bear the NKH1 marker. In contrast, the CD3* lymphocyte subset
showed lower but consistent levels of cytotoxic activity. The CD8+ lymphocyte
subset appeared to contribute no cytotoxic activity against either of the NK-
resistant target cells, however, considerable loss ofactivity was seen compared to
unseparated PBL. To further investigate the role ofCD8' effector cell, purified
T cells were cultured for 4 d and then separated into CD4' or CD4- subsets.
Table IV shows a representative experiment indicating that CD8' effector cells
were active against OVCA, whereas CD8-, CD4+ cells were devoid ofsignificant
cytolytic activity. However, when the total contribution to cytotoxic activity of
Cells staining positively Cytolytic activity against:
Effector cells
for:
from: MBL2 OVCA
CD3 CD8 NKH1
LU/10' cells Total LU LU/10' cells Total LU
Unseparated PBL 95 34 7 25.8 68 16 28
CD3' 98 36 8 1.7 1.3 12 35
CD3- 14 11 97 108 76 60 43
CD8' 97 87 85 1 <1 <1 <1
CD8- 96 12 24 16 5 6 21200
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TABLE IV
Characterization of TEffector Cells Mediating LAKActivity
Effector cells
from:
1QAoo3
Cells staining
￿
Cytolytic activity against
positively for:
￿
OVCA
Characterizations performed 4 d after IL-2 activation. See previous tables
for details.
PBL
￿
Fr 1
￿
Fr 2
￿
Fr 3
￿
Fr 4
￿
Fr 5
￿
Fr 6
Population
FIGURE 4.
￿
Frequencyanalysis of LAKeffector. Limiting-dilution frequencyanalysis of LAK
effector cells was performed on day 4. The effector function of the various dilutions was
measured for cytotoxicity against FEMX target cellson day 4. Results show the frequency (±
95% confidence interval) basedon limiting-dilution X' analysis.
the various subsets was calculated, it was apparent that the CD3+ and CD3-
population contributed significantly to the lysis of fresh ovarian carcinoma cells.
Effector Cell Frequency Analysis. To directly examine the phenotype and
frequency ofeffector cells in variouspopulations of cells, unseparated peripheral
blood mononuclear cells were cultured after depletion of monocytes or B cells,
or after fractionation on discontinuous Percoll gradients. Cells were cultured for
4 d in bulk cultures at 4 X 106 cells/ml, and the effector frequency was
determined using limiting-dilution frequency analysis at day 4. A typical result
of this type of experiment is shown in Fig. 4. As in the direct cytotoxicity assays,
considerably more effector cells were present in the low-density LGL-enriched
fractions than in the high-density fractions, which are predominantly composed
of CD3+ T cells. Again, based on a number of experiments, it is clear that,
generally, 10-40 times more effector cells are found in the low-density Percoll
fractions than in the high-density, T cell-enriched fractionated lymphocytes,
indicating a high level ofeffector frequency in LGL (CDw16+, NKHI') effector
populations.
Analysis of Effector Cell Receptors Involved in Mediating Lysis.
￿
Because two
phenotypically distinct lymphocyte subsets mediate lytic activity against NK-
susceptible target cells, we wished to determine which effector cell receptors
CD3 CD4 CD8 LU/10' cells Total LU
Unseparated T 98 45 52 6.3 30
CD4* 97 ND 7 <0.1 <1
CD4- 97 3 89 30.6 4120
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FIGURE 5.
￿
Effect of anti-CD determinants on LAK activity in PBL, LGL, andT cells. PBL
(A and B), LGL (C andD), and T cells (E and F) were cultured for 4 d, and their NK (A, C,
andE; tested against K562) and LAK(B, D, andF; tested against FEMX)activity wasmeasured
after various amounts of anti-CD3 (0), anti-CD4 (p), anti-CD8 (A), and Leu-M3 (/) were
added. The hatched area represents the percentage of control activity (t1.5 SD; p <_ 0.05).
Activity was measured in a 4-h "Cr-release assay with the antibodies present during the entire
assay.
might be involved. Therefore, antibodies directed against the CD3, CD4, CD8,
CDw16, and NKH1 markers, some of which have been shown (11) to be involved
in and to inhibit various cytotoxic activities of fresh T cells and T cell clones,
were assayed against NK-susceptible K562 target cells and FEMX cells. A
representative experiment is shown in Fig. 5. Antibody to Leu-M3, a monocyte-
specific IgG antibody, was used as a control to measure nonspecific inhibition by
antibody. If we used either FEMX or K562 target cells, we saw significant specific
inhibition ofcytotoxicity with CD3 determinant reagent, especially in populations1202
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containing a high percentage of T cells. In addition, CD8 determinant antibodies
moderately inhibited LAK (FEMX) and NK (K562) target cells, especially in T
cell-enriched populations. However, LGL cytotoxicity was not inhibited to any
significant extent, against either K562 or FEMX cells. Antibodies directed to
CD 16 or NKH1 had no effect against any target (data not shown). Although
some inhibition of LGL-mediated lysis was seen with the CD3 and CD8 deter-
minants, this level was not significantly different than that demonstrated by the
Leu-M3 (IgG) control, and was only apparent at the highest dose administered
(100 Ecg/ml). Therefore, it appears that most of the activity mediated by T cells
is regulated through the T cell receptor complex, whereas the LGL fraction is
not inhibited by antibodies directed against the CD3 or CD8 determinants.
Discussion
By definition, cytolysis mediated by LAK cells does not occur without stimu-
lation. In contrast, NK cells purified on Percoll density gradients have some lytic
activity against selected cultured and fresh tumor cells, but this has been dem-
onstrated (11) against only a limited number of tumors. However, the target cell
specificity of LAK cells and activated NK cells is very similar; both cell types can
kill fresh tumor cell lines, 1,3,5-trinitrophenyl-modified cells, and virus-infected
cells. LAK cells are stimulated mainly by IL-2, whereas NK cells are regulated
by IL-I, and various species of IFN, as well as IL-2 (6, 11).
The study described here involved an in-depth analysis of the cells that
generate LAK activity. This analysis of progenitor cells relied on phenotypic
characterization, separation on Percoll gradients, and LDA to determine pro-
genitor frequency. We have demonstrated that CD3+ and CD3- cells can gen-
eratecytotoxic cells, termed LAK cells, from normal PBL. Although the effector
cell that is isolated from whole PBL varies somewhat (depending on the target
cell), the primary effector cell is coincident with the LGL population on day 0,
the CDw16+, NKH1', activated NK cell.
The nature of the bone marrow progenitor phenotype of NK cells has been
extensively studied, and differs considerably from the mature NK cell phenotype.
The major NK progenitor cell has been characterized as having a phenotype of
CD3-, CD8-, OKTI I-, OKM1 -, CDw16-, and NKH1 - (17). Our studies with
limiting-dilution frequency analysis, which accurately assesses the frequency of a
progenitor, are in partial agreement with the earlier report of Grimm et al . (8).
However, our studies have indicated that more than one effector cell population
is involved in generating what is known as LAK activity. Clearly, a CD3+ cell
contributes a small but significant amount to rIL-2-generated cytotoxicity. How-
ever, an LGL population that is CD3-, CD8- but bears the CDw16 and NKH1
markerscontributes most of the rIL-2-generated LAKactivity. This latter finding
is consistent with a recent report of cytolytic activity of CDw16+-activated killers
(10) against fresh melanoma tissue (10). The effector phenotype of LAK cells
generated from unseparated PBL was originally reported to be CD3+ and TI I+
(8).
Our results on effector cell frequency obtained using positive and negative
selection procedures, and LDA, indicate that the actual cytotoxic effector cells
are of a considerably different phenotype than was previously reported (7-9).ORTALDO ET AL.
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The effector frequency that is measured after lymphokine activation is highest
in the low-density CD3- populations. Lytic unit calculations ofcytotoxicity against
fresh tumor cells and NK-resistant tumor cell lines such as FEMX yield the same
results. The reason for the discrepancy between this and previous reports (7-9)
is not clear; however, it may relate to the techniques that were used to analyze
effector cells. These investigators (7-9) have used complement-dependent lysis
to deplete populations ofthe desired effector cell. The ability ofcomplement to
lyse cultured cells, and the problems associated with modulating surface markers
in vitro may have accounted for some of the discrepancy between our results
and those of other researchers (10). However, by using direct isolation proce-
dures, and by reanalyzing the populations used as effector cells, our study has
clearly indicated that this LAK effect does not involve a single effector cell. In
contrast to previous reports, the major effector cell does not appear to bear the
CD3 marker associated with the T cell receptor, but seemstobea CD3-activated
killer cell that closely resembles the NK cell, in that CDw16 and NKH1 markers
are present.
The kinetics of cytotoxicity generation differ somewhat in these populations.
CD3+ cells require 2-3 d to generate maximal activity, whereas LGL-enriched
populations are efficiently activated and show high levels of killing against both
cultured and fresh tumor cells within 24 h of IL-2 treatment.
It is unlikely that a single cell type serves as the LAK progenitor, because both
CD3', CDw16- and CD3-, CDw16+cells can be activatedby rIL-2. These subsets
also mediate LAK activity to different degrees. Therefore, the overall results
suggest that LAK is not generated from a unique precursor or mediated by a
unique effector. As a result, we conclude that LAK cells are generated from
several different lymphocyte precursors, and that the cytotoxic effector cell
population consists of several different cell types that contribute to the overall
cytotoxicity, with LGL contributing the major portion ofthe activity.
Our analysis of the receptors involved in the activation ofthese various subset
populations supports the conclusion that several cell types generate LAK. This
is especially obvious when the CD3-directed mAb are used to inhibit cytotoxic
activity. These CD3 antibodies have been shown (11) to inhibit cultured as well
as cloned populations of cytotoxic T lymphocytes that interact with the CD3
determinant, which is a part ofthe T cell receptor. Therefore, these results allow
us to conclude that T cell receptor-associated cytotoxicity is responsible for part
ofwhat is known as LAK activity, but that most LAK activity, on a per-cell basis,
occurs through a cytolytic function presumably mediated by T cell receptor-
negative LGL (NK cells) . Although our data do not identify an NK receptor,
they do indicate a difference from T cells and the lack of T cell receptor
involvement. Although an NK cell receptor has not been defined to date, the
activity of these effectors and the parallel with T cell killing via the T cell
receptor supports the contention that an NK cell receptor exists.
In summary, we have defined and characterized the lymphocyte populations
responsible for generating and mediatingthe cytotoxicity knownas LAKactivity,
and have shown that different receptors on the different cell types are involved
in expression of LAK activity.1204
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Summary
IL-2 has been examined for its ability to regulate lymphokine-activated killer
(LAK) activity. IL-2 is a potent activator of cytolytic activity against a wide array
of tumor cells, including those from fresh autologous and allogeneic tumors.
Using subpopulations of lymphoid cells that were separated on Percoll density
gradients, and subsequently purified by immunoadsorbance, studies were per-
formed to examine the phenotypes of progenitor and effector cells of human
LAK cells and to compare them with the phenotype of activated NK cells. From
these studies, it was evident that several lymphoid subsets, including CD3+,
CDw16- and CD3-, CDw16' cells could mediate LAK lysis of fresh tumor cells.
Our examination of the kinetics of activation revealed that CDw16', NKH1 +
(NK-active) cells were maximally activated by 1-2 d . In contrast, CD3+ cells
appeared not to achieve maximal cytolytic activity against fresh and cultured
tumor cells until days 2-3. Using limiting-dilution frequency analysis, we showed
that a large percentage of cytolytically active progenitors was present among the
CDw16+, NKHI' cells. The progenitor and effector cell frequencies appear to
be 10-50 times higher in these populations compared to CD3+ cells. In addition,
the selective blockage by mAb to the CD3 determinant of the T cell receptor
complex indicated that these two effector cell phenotypes relied on different
receptors to mediate their cytotoxic activity against tumor cells. Therefore, the
accumulated data suggest that there is not a single unique progenitor of LAK
activity, but rather that multiple subsets of lymphocytes become cytotoxic in
response to IL-2. However, the NK cell population forms the largest single
component of LAK cell activity in human peripheral blood.
Received forpublication 15 May 1986 and in revised form 30June 1986.
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